Vascular Therapy and Associated Products 2028
In plain English
The notice doesn't say
Who holds it now
Last won by Convatec Limited and CREED MEDICAL LTD T/A Creed Health and KCI Medical Limited and 3 more in Nov 2026, for £136m.
- Negative Pressure Wound TherapyConvatec Limited, CREED MEDICAL LTD T/A Creed Health, KCI Medical Limited and 3 more £136m
- Patient Temperature Management 2027Aquilant Limited, Central Medical Supplies Limited, GBUK Ltd and 31 more £1.4bn
- Infusion Pumps, Administration Sets and Associated Products 2026Aquilant Limited, Arcomedical Infusion Limited, B. Braun Medical Limited and 20 more £340m
What you're up against
- The same firms have won it the last 2 times: expect them to bid again, and to know the work well.
- 57 different firms won this buyer's 3 awards for this kind of work in 2026.
- It last went for £135.7m in 2026.
- The last award named 6 suppliers: it may be a framework, where many firms are chosen.
The notice as published
NHS Supply Chain seeks to establish a framework agreement for the supply of Vascular Therapy and Associated Products. The framework will provide a range of products for acute and chronic vascular therapy requirements and is divided into two Lots: Lot 1: Acute Therapy Products Lot 2: Chronic Therapy Products Tenderers may tender for one or both Lots. The framework will support NHS Supply Chain and its customers through applicable routes of supply, including Stocked, eDirect and Direct routes, as further described in the procurement documents. The framework will be available for use by NHS Trusts, other NHS entities, government departments, agencies and other statutory bodies, including local authorities, and private sector entities active in the UK healthcare sector, in accordance with the procurement documents. The anticipated value of the Framework Agreement for the initial twenty-four (24) month term is approximately £46,230,000 excluding VAT. The Authority may extend the Framework Agreement by up to two further periods of twelve (12) months each. The anticipated total value over the maximum forty-eight (48) month term, including the extension options, is approximately £96,630,000 excluding VAT. These values are estimates based on historical usage and forecast demand and do not constitute a guarantee of expenditure or business under the Framework Agreement. Supply of vascular therapy products for acute therapy requirements, as further described within the Specification and associated procurement documents. Supply of vascular therapy products for chronic therapy requirements, as further described within the Specification and associated procurement documents.